Menu
Enrolling by invitation NCT06315023

The Percutaneous Transmural Arterial Bypass -1 Study (Post Approval Registry)

Observational Peripheral Arterial Disease Symptomatic Femoropopliteal Lesions

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: DETOUR System.
Who it may be relevant to
Registry conditions: Peripheral Arterial Disease, Symptomatic Femoropopliteal Lesions. Basic parameters: No limits · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Prospective, Single Arm, Registry-based Study to Evaluate the Real-world Use of the DETOUR™ System in US Patients

Overview

The purpose of this post-market surveillance study will be to evaluate the real-world use of the DETOUR System in treated patients with symptomatic femoropopliteal lesions from 200 mm to 460 mm in length with chronic total occlusions (100 mm to 425 mm) or diffuse stenosis \> 70% who may be considered suboptimal candidates for surgical or alternative endovascular treatments.

Detailed description

A maximum of 450 subjects will be enrolled with a target study population of at least 200 evaluable female and 200 evaluable male participants at the 12-month post-procedure follow-up visit. A maximum of 200 US sites. Sites will be selected that participate or will participate in the VQI PVI Registry. Follow up visits/assessments will be completed at 1, 12, 24-, 36-, 48-, and 60-months post-procedure. Study enrollment is expected to conclude over 4 years. Follow up data at 1 year is expected to conclude in 5 years from enrollment, with 5-year follow up expected to conclude in 9 years from enrollment.

Interventions

  • Device DETOUR System
    Percutaneous Transmural Arterial Bypass Therapy using the DETOUR™ System

Primary outcome measures

  • Freedom from CD-TLR [Time frame: 1 Year]
  • Freedom from MAE [Time frame: 30 Days]

Eligibility criteria

Inclusion Criteria: Participants should be a candidate for the DETOUR System as assessed by the treating physician after review of the clinical and anatomic Indications for Use.

\-

Exclusion Criteria: There are no exclusion criteria. All cases entered in the registry at participating institutions will be included up through the targeted goals per the enrollment plan.

\-

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Case-only

Study locations

United States · 10 centers
  • Salinas Valley Memorial Hospital — Salinas
  • University of Connecticut — Storrs
  • Medstar Washington Hospital Center — Washington D.C.
  • Delray Medical Center — Delray Beach
  • Beth Isreal Deaconess Medical Center — Boston
  • Saint Luke's Hospital of Kansas City — Kansas City
  • NYU Langone Medical Center — New York
  • Cleveland Clinic Main Campus — Cleveland
  • … and 2 more centers

Identifiers

NCT: NCT06315023 · CP-0029

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗